UPDATE: Piper Jaffray Downgrades Affymax to Neutral Following Omontys Recall

Piper Jaffray downgraded Affymax AFFY from Overweight to Neutral and removed the $37.00 price target. Piper Jaffray commented, "We are downgrading AFFY to Neutral following a voluntary safety recall of Omontys. We expect the stock to approach cash value (~$2 per share) tomorrow as investors take into account the lack of visibility on reintroduction of the drug and more importantly the difficult task of repairing a negative safety perception. This combined with a potential delay in approval in Europe and need for additional financing in the future could prevent the stock from recovering in the next 6-9 months." Affymax closed at $16.52 on Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorDowngradesAnalyst RatingsPiper Jaffray
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!